All Outputs (2)

TRPC6 Binds to and Activates Calpain, Independent of Its Channel Activity, and Regulates Podocyte Cytoskeleton, Cell Adhesion, and Motility (2019)
Journal Article
Farmer, L., Rollason, R., Whitcomb, D., Ni, L., Goodlif, A., Lay, A., Birnbaumer, L., Heesom, K., Xu, S.-Z., Saleem, M., & Welsh, G. (2019). TRPC6 Binds to and Activates Calpain, Independent of Its Channel Activity, and Regulates Podocyte Cytoskeleton, Cell Adhesion, and Motility. Journal of the American Society of Nephrology : JASN, 30(10), 1910-1924. https://doi.org/10.1681/ASN.2018070729

BACKGROUND:
Mutations in the transient receptor potential channel 6 (TRPC6) gene are associated with an inherited form of FSGS. Despite widespread expression, patients with TRPC6 mutations do not present with any other pathologic phenotype, suggesti... Read More about TRPC6 Binds to and Activates Calpain, Independent of Its Channel Activity, and Regulates Podocyte Cytoskeleton, Cell Adhesion, and Motility.

Mibefradil, a T-type Ca2+ channel blocker also blocks Orai channels by action at the extracellular surface (2019)
Journal Article
Li, P., Rubaiy, H. N., Chen, G.-L., Hallett, T., Zaibi, N., Zeng, B., Saurabh, R., & Xu, S.-Z. (2019). Mibefradil, a T-type Ca2+ channel blocker also blocks Orai channels by action at the extracellular surface. British Journal of Pharmacology, 176, 3845–3856. https://doi.org/10.1111/bph.14788

Background and purpose
Mibefradil (Mib), a T‐type Ca2+ channel blocker, has been investigated for treating solid tumours. However, its underlying mechanisms are still unclear. Here we aimed to investigate the pharmacological aspect of Mib on ORAI st... Read More about Mibefradil, a T-type Ca2+ channel blocker also blocks Orai channels by action at the extracellular surface.